Aptamer-functionalized AuNCs nanogel for targeted delivery of docosahexaenoic acid to induce browning of white adipocytes

Xu, Hejie; Ding, Jialuo; Du, Yukou; Li, Le; Li, Yeying; Zhao, Mengyuan; Sui, Yu; Lin, Zhenkun

doi:10.1039/d2tb02709g

Cited by 3 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following that, the team developed a targeted delivery vehicle for the browning agent docosahexaenoic acid (DHA@Apt-NG) which notably enhanced the mRNA expression levels of Prdm16 , Pparg , Pgc-1α , and Ucp1 . This study presents a viable approach for achieving effective browning of white adipocytes using targeted delivery nano-systems, thereby providing novel insights for the treatment of obesity [ 127 ]. In addition, a novel nanocomposite utilizing mesoporous silica-coated CeO 2 nanozymes was developed.…”

Section: The Application Of Nanozyme In Metabolic Disease Managementmentioning

confidence: 99%

Nanozyme as a rising star for metabolic disease management

Wang,

He,

Huang

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Nanozyme, characterized by outstanding and inherent enzyme-mimicking properties, have emerged as highly promising alternatives to natural enzymes owning to their exceptional attributes such as regulation of oxidative stress, convenient storage, adjustable catalytic activities, remarkable stability, and effortless scalability for large-scale production. Given the potent regulatory function of nanozymes on oxidative stress and coupled with the fact that reactive oxygen species (ROS) play a vital role in the occurrence and exacerbation of metabolic diseases, nanozyme offer a unique perspective for therapy through multifunctional activities, achieving essential results in the treatment of metabolic diseases by directly scavenging excess ROS or regulating pathologically related molecules. The rational design strategies, nanozyme-enabled therapeutic mechanisms at the cellular level, and the therapies of nanozyme for several typical metabolic diseases and underlying mechanisms are discussed, mainly including obesity, diabetes, cardiovascular disease, diabetic wound healing, and others. Finally, the pharmacokinetics, safety analysis, challenges, and outlooks for the application of nanozyme are also presented. This review will provide some instructive perspectives on nanozyme and promote the development of enzyme-mimicking strategies in metabolic disease therapy. Graphical Abstract

show abstract

Section: The Application Of Nanozyme In Metabolic Disease Managementmentioning

confidence: 99%

Nanozyme as a rising star for metabolic disease management

Wang,

He,

Huang

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…DNA aptamers are screened synthetic DNA oligonucleotides that can bind to various specific targets [ 196 ]. Surface functionalization of DNA aptamers endows nanoparticle with unique ability to specifically recognize various targets.…”

Section: Tumor Interactionsmentioning

confidence: 99%

Biological Interaction and Imaging of Ultrasmall Gold Nanoparticles

Sang,

Luo,

Liu

2023

Nano-Micro Lett.

View full text Add to dashboard Cite

Highlights The ultrasmall gold nanoparticles (AuNPs), serving as a bridge between small molecules and traditional inorganic nanoparticles, create significant opportunities to address many challenges in the health field. This review discusses the recent advances in the biological interactions and imaging of ultrasmall AuNPs. The challenges and the future development directions of the ultrasmall AuNPs are presented. Abstract Ultrasmall gold nanoparticles (AuNPs) typically includes atomically precise gold nanoclusters (AuNCs) and AuNPs with a core size below 3 nm. Serving as a bridge between small molecules and traditional inorganic nanoparticles, the ultrasmall AuNPs show the unique advantages of both small molecules (e.g., rapid distribution, renal clearance, low non-specific organ accumulation) and nanoparticles (e.g., long blood circulation and enhanced permeability and retention effect). The emergence of ultrasmall AuNPs creates significant opportunities to address many challenges in the health field including disease diagnosis, monitoring and treatment. Since the nano–bio interaction dictates the overall biological applications of the ultrasmall AuNPs, this review elucidates the recent advances in the biological interactions and imaging of ultrasmall AuNPs. We begin with the introduction of the factors that influence the cellular interactions of ultrasmall AuNPs. We then discuss the organ interactions, especially focus on the interactions of the liver and kidneys. We further present the recent advances in the tumor interactions of ultrasmall AuNPs. In addition, the imaging performance of the ultrasmall AuNPs is summarized and discussed. Finally, we summarize this review and provide some perspective on the future research direction of the ultrasmall AuNPs, aiming to accelerate their clinical translation.

show abstract